Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 101 to 125 of 383

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]	Technology appraisal guidance	TBC
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)	NICE guideline	31 March 2025
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]	Technology appraisal guidance	TBC
Efgartigimod for treating generalised myasthenia gravis [ID4003]	Technology appraisal guidance	TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]	Technology appraisal guidance	TBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]	Technology appraisal guidance	TBC
Elafibranor for treating primary biliary cholangitis [ID6331]	Technology appraisal guidance	TBC
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]	Technology appraisal guidance	TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer ID6177	Technology appraisal guidance	TBC
Endometriosis: diagnosis and management - diagnosing endometriosis	NICE guideline	11 July 2024
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma	Interventional procedures guidance	TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]	Technology appraisal guidance	TBC
Epilepsies in children, young people and adults (extraordinary review)	NICE guideline	TBC
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]	Technology appraisal guidance	14 August 2024
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]	Technology appraisal guidance	TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]	Technology appraisal guidance	29 January 2025
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]	Technology appraisal guidance	TBC
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]	Technology appraisal guidance	11 September 2024
Evobrutinib for treating relapsing multiple sclerosis [ID6313]	Technology appraisal guidance	TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]	Technology appraisal guidance	TBC
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]	Technology appraisal guidance	TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests	Diagnostics guidance	TBC

Results per page

10
25
50
All